---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013040"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:54:48.840086+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data

## Summary
- Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.
- ENV105 is a first-in-class CD105 antagonist; interim safety analysis (July 2025) showed well-tolerated with no dose-limiting toxicities or Grade 3/4 events.
- Speakers include principal investigators Drs. Bhowmick, Swami, Lee, and Posadas.
- ENV105 targets CD105-driven drug resistance in castration-resistant prostate cancer; trial combines ENV105 with apalutamide.

## SEC filing metadata
- accession: 0001493152-25-013040
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/0001493152-25-013040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013040
- JSON: https://secwatch.observer/filing/0001493152-25-013040.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.